A Combined Pharmacodynamic Quantitative and Qualitative Model Reveals the Potent Activity of Daptomycin and Delafloxacin against Staphylococcus aureus Biofilms

被引:112
|
作者
Bauer, Julia [1 ]
Siala, Wafi [1 ]
Tulkens, Paul M. [1 ]
Van Bambeke, Francoise [1 ]
机构
[1] Catholic Univ Louvain, Louvain Drug Res Inst, B-1200 Brussels, Belgium
关键词
PSEUDOMONAS-AERUGINOSA BIOFILMS; HIGH-DOSE DAPTOMYCIN; IN-VITRO ACTIVITIES; METHICILLIN-RESISTANT; ANTIBIOTIC SUSCEPTIBILITY; INFECTIVE ENDOCARDITIS; ANTIMICROBIAL THERAPY; BACTERIAL BIOFILMS; MATURE BIOFILM; VANCOMYCIN;
D O I
10.1128/AAC.00181-13
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Biofilms are associated with persistence of Staphylococcus aureus infections and therapeutic failures. Our aim was to set up a pharmacodynamic model comparing antibiotic activities against biofilms and examining in parallel their effects on viability and biofilm mass. Biofilms of S. aureus ATCC 25923 (methicillin-sensitive S. aureus [MSSA]) or ATCC 33591 (methicillin-resistant S. aureus [MRSA]) were obtained by culture in 96-well plates for 6 h/24 h. Antibiotic activities were assessed after 24/48 h of exposure to concentrations ranging from 0.5 to 512 times the MIC. Biofilm mass and bacterial viability were quantified using crystal violet and the redox indicator resazurin. Biofilms stained with Live/Dead probes were observed by using confocal microscopy. Concentration-effect curves fitted sigmoidal regressions, with a 50% reduction toward both matrix and viability obtained at sub-MIC or low multiples of MICs against young biofilms for all antibiotics tested. Against mature biofilms, maximal efficacies and potencies were reduced, with none of the antibiotics being able to completely destroy the matrix. Delafloxacin and daptomycin were the most potent, reducing viability by more than 50% at clinically achievable concentrations against both strains, as well as reducing biofilm depth, as observed in confocal microscopy. Rifampin, tigecycline, and moxifloxacin were effective against mature MRSA biofilms, while oxacillin demonstrated activity against MSSA. Fusidic acid, vancomycin, and linezolid were less potent overall. Antibiotic activity depends on biofilm maturity and bacterial strain. The pharmacodynamic model developed allows ranking of antibiotics with respect to efficacy and potency at clinically achievable concentrations and highlights the potential utility of daptomycin and delafloxacin for the treatment of biofilm-related infections.
引用
收藏
页码:2726 / 2737
页数:12
相关论文
共 50 条
  • [31] Bromophenazine derivatives with potent inhibition, dispersion and eradication activities against Staphylococcus aureus biofilms
    Garrison, Aaron T.
    Bai, Fang
    Abouelhassan, Yasmeen
    Paciaroni, Nicholas G.
    Jin, Shouguang
    Huigens, Robert W., III
    RSC ADVANCES, 2015, 5 (02) : 1120 - 1124
  • [32] Improved Activity of Rifampicin Against Biofilms of Staphylococcus aureus by Multicomponent Complexation
    Cordoba, Antonella V. Dan
    Aiassa, Virginia
    Longhi, Marcela R.
    Quevedo, Mario A.
    Zoppi, Ariana
    AAPS PHARMSCITECH, 2020, 21 (05)
  • [33] Elucidating the antibiofilm activity of Frangula emodin against Staphylococcus aureus biofilms
    Dukanovi, Stefana
    Ganic, Tea
    Loncarevic, Branka
    Cvetkovic, Stefana
    Nikolic, Biljana
    Tenji, Dina
    Randjelovic, Danijela
    Mitic-Culafic, Dragana
    JOURNAL OF APPLIED MICROBIOLOGY, 2022, 132 (03) : 1840 - 1855
  • [34] Antibacterial activity of ruthenium polypyridyl complexes against Staphylococcus aureus and biofilms
    Simeng Bu
    Guijuan Jiang
    Guangbin Jiang
    Jinyao Liu
    Xiaoli Lin
    Jihong Shen
    Yanshi Xiong
    Xuemin Duan
    Jintao Wang
    Xiangwen Liao
    JBIC Journal of Biological Inorganic Chemistry, 2020, 25 : 747 - 757
  • [35] Activity of a designed cyclic analogue of gomesin against Staphylococcus aureus biofilms
    Silva Herdade, A.
    Dias, S. A.
    Pinto, S. N.
    Cheneval, O.
    Craik, D. J.
    Coutinho, A.
    Castanho, M. A.
    Henriques, S. T.
    Veiga, A. S.
    FEBS OPEN BIO, 2022, 12 : 34 - 34
  • [36] Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model (vol 57, pg 66, 2013)
    Werth, Brian J.
    Sakoulas, George
    Rose, Warren E.
    Pogliano, Joseph
    Tewhey, Ryan
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (03) : 1565 - 1565
  • [37] Evaluation of Ceftaroline, Vancomycin, Daptomycin, or Ceftaroline plus Daptomycin against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations
    Werth, Brian J.
    Barber, Katie E.
    Ireland, Cortney E.
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (06) : 3177 - 3181
  • [38] Evaluation of Ceftaroline Activity versus Daptomycin (DAP) against DAP-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Strains in an In Vitro Pharmacokinetic/Pharmacodynamic Model
    Steed, Molly
    Vidaillac, Celine
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (07) : 3522 - 3526
  • [39] The Combination of Daptomycin and Fosfomycin Has Synergistic, Potent, and Rapid Bactericidal Activity against Methicillin-Resistant Staphylococcus aureus in a Rabbit Model of Experimental Endocarditis
    Garcia-de-la-Maria, Cristina
    Gasch, Oriol
    Garcia-Gonzalez, Javier
    Soy, Dolors
    Shaw, Evelyn
    Ambrosioni, Juan
    Almela, Manel
    Pericas, Juan M.
    Tellez, Adrian
    Falces, Carlos
    Hernandez-Meneses, Marta
    Sandoval, Elena
    Quintana, Eduard
    Vidal, Barbara
    Tolosana, Jose M.
    Fuster, David
    Llopis, Jaume
    Pujol, Miquel
    Moreno, Asuncion
    Marco, Francesc
    Miro, Jose M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (06)
  • [40] Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model
    Lister, PD
    CLINICAL INFECTIOUS DISEASES, 2001, 32 : S33 - S38